Isabel Alvarez Lopez

Dr. Isabel Alvarez Lopez


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
LGLuca Gianni
Luca Gianni
MMMauro Mansutti
Mauro Mansutti
AAAntonio Anton
Antonio Anton
LCLourdes Calvo
Lourdes Calvo
GBGiancarlo Bisagni
Giancarlo Bisagni
ITIgnacio Tusquets
Ignacio Tusquets
Pathologic complete response (pCR) after neoadjuvant therapy of breast cancer is a surrogate end point of individual long-term benefit,1,2 and allows for rapid testing of new therapies, and discovery or validation of predictive or prognostic biomarkers.3 The growing number of candidate new drugs and the established awareness that breast cancer is a group of different diseases with different molecular characteristics and different sensitivity to therapies has led to a greater interest in evaluating these agents in a neoadjuvant setting. The latter approach is an easily applicable clinical tool to rapidly rank the antitumor activity of new therapies in subgroups of patients selected for homogeneous molecular characteristics of the tumor.4

1 April 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AAAngela M. Araujo
Angela M. Araujo
AAAndrea Abaurrea
Andrea Abaurrea
PAPeio Azcoaga
Peio Azcoaga
JLJoanna I. López-Velazco
Joanna I. López-Velazco
SMSara Manzano
Sara Manzano
CLCharles Lawrie
Charles Lawrie
The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression.

2 November 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
BMBegoña Martin-Castillo
Begoña Martin-Castillo
SPSonia Pernas
Sonia Pernas
JDJoan Dorca
Joan Dorca
ILIsabel Alvarez Lopez
Isabel Alvarez Lopez
SMSusana Martínez
Susana Martínez
Javier A. MenendezJavier A. Menendez
Javier A. Menendez
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study

24 February 2016 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
MMMiguel Martin
Miguel Martin
JBJan Christoph Brase
Jan Christoph Brase
ARAmparo Ruiz
Amparo Ruiz
APAleix Prat
Aleix Prat
RKRalf Kronenwett
Ralf Kronenwett
ARAlvaro Rodriguez-Lescure
Alvaro Rodriguez-Lescure
There are several prognostic multigene-based tests for managing breast cancer (BC), but limited data comparing them in the same cohort. We compared the prognostic performance of the EndoPredict (EP) test (standardized for pathology laboratory) with the research-based PAM50 non-standardized qRT-PCR assay in node-positive estrogen receptor-positive (ER+) and HER2-negative (HER2−) BC patients receiving adjuvant chemotherapy followed by endocrine therapy (ET) in the GEICAM/9906 trial. EP and PAM50 risk of recurrence (ROR) scores [based on subtype (ROR-S) and on subtype and proliferation (ROR-P)] were compared in 536 ER+/HER2− patients. Scores combined with clinical information were evaluated: ROR-T (ROR-S, tumor size), ROR-PT (ROR-P, tumor size), and EPclin (EP, tumor size, nodal status). Patients were assigned to risk-categories according to prespecified cutoffs. Distant metastasis-free survival (MFS) was analyzed by Kaplan–Meier. ROR-S, ROR-P, and EP scores identified a low-risk group with a relative better outcome (10-year MFS: ROR-S 87 %; ROR-P 89 %; EP 93 %). There was no significant difference between tests. Predictors including clinical information showed superior prognostic performance compared to molecular scores alone (10-year MFS, low-risk group: ROR-T 88 %; ROR-PT 92 %; EPclin 100 %). The EPclin-based risk stratification achieved a significantly improved prediction of MFS compared to ROR-T, but not ROR-PT. All signatures added prognostic information to common clinical parameters. EPclin provided independent prognostic information beyond ROR-T and ROR-PT. ROR and EP can reliably predict risk of distant metastasis in node-positive ER+/HER2− BC patients treated with chemotherapy and ET. Addition of clinical parameters into risk scores improves their prognostic ability.

1 January 2014 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
ALAna Lluch
Ana Lluch
ILIsabel Alvarez Lopez
Isabel Alvarez Lopez
MMMontserrat Muñoz
Montserrat Muñoz
MSMiguel Ángel Seguí
Miguel Ángel Seguí
ITIgnasi Tusquets
Ignasi Tusquets
LGLaura García-Estévez
Laura García-Estévez

1 August 2017 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JMJames P. Morden
James P. Morden
ILIsabel Alvarez Lopez
Isabel Alvarez Lopez
GBGianfilippo Bertelli
Gianfilippo Bertelli
ACAlan S. Coates
Alan S. Coates
RCRobert Coleman
Robert Coleman
RCR. Charles Coombes
R. Charles Coombes
Purpose: The Intergroup Exemestane Study, an investigator-led study of 4,724 postmenopausal patients with early breast cancer (clinical trial information: ISRCTN11883920), has previously demonstrated that a switch from adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane was associated with clinically relevant improvements in efficacy. Here, we report the final efficacy analyses of this cohort. Patients and Methods: Patients who remained disease free after 2 to 3 years of adjuvant tamoxifen were randomly assigned to continue tamoxifen or switch to exemestane to complete a total of 5 years of adjuvant endocrine therapy. Given the large number of non–breast cancer–related deaths now reported, breast cancer–free survival (BCFS), with censorship of intercurrent deaths, was the primary survival end point of interest. Analyses focus on patients with estrogen receptor-positive or unknown tumors (n = 4,599). Results: At the time of the data snapshot, median follow-up was 120 months. In the population that was estrogen receptor positive or had unknown estrogen receptor status, 1,111 BCFS events were observed with 508 (22.1%) of 2,294 patients in the exemestane group and 603 (26.2%) of 2,305 patients in the tamoxifen group. The data corresponded to an absolute difference (between exemestane and tamoxifen) at 10 years of 4.0% (95% CI, 1.2% to 6.7%), and the hazard ratio (HR) of 0.81 (95% CI, 0.72 to 0.92) favored exemestane. This difference remained in multivariable analysis that was adjusted for nodal status, prior use of hormone replacement therapy, and prior chemotherapy (HR, 0.80; 95% CI, 0.71 to 0.90; P < .001). A modest improvement in overall survival was seen with exemestane; the absolute difference (between exemestane and tamoxifen) at 10 years in the population that was estrogen receptor positive or had unknown estrogen receptor status was 2.1% (95% CI, −0.5% to 4.6%), and the HR was 0.89 (95% CI, 0.78 to 1.01; P = .08). For the intention-to-treat population, the absolute difference was 1.6% (95% CI, −0.9% to 4.1%); the HR was 0.91 (95% CI, 0.80 to 1.03, P = .15). No statistically significant difference was observed in the proportion of patients who reported a fracture event in the post-treatment period. Conclusion: The Intergroup Exemestane Study and contemporaneous studies have established that a strategy of switching to an aromatase inhibitor after 2 to 3 years of tamoxifen can lead to sustained benefits in terms of reduction of disease recurrence and breast cancer mortality.